RxDoctor Payments Data

Ty Hanson, DO

Dermatology · Aberdeen, SDNPI 1396804597

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $819,512 of the $982,075 with a category attached, or 83.4%. 25 manufacturers reported payments, led by Lilly USA, LLC at 30.6% of the total. Among dermatology clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$982,075in general payments, 2019–2025

Across 1,589 payments — averaging $618.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$301K
  • AbbVie$145K
  • Johnson & Johnson$120K
  • Regeneron Healthcare Solutions, Inc.$97K
  • Amgen$51K
  • UCB, Inc.$50K
  • plus $218K from 19 others

What the payments were for

  • Consulting fees$21,9082%
  • Speaking & faculty fees$819,51283%
  • Travel & lodging$114,06012%
  • Food & beverage$25,7623%
  • Education$8330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$982,075 in reported general payments places this provider in the 95th percentile of 44 dermatology providers in South Dakota.

See all dermatology providers in South Dakota

Medicare billing

Part B allowed, 2024
$1,806,399
Medicare patients
1,114
Services billed
15,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast27$131,076
Dupixent PenDupilumab32$121,496
Tacrolimus32$5,534
Fluorouracil38$3,182
CiclopiroxCiclopirox Olamine47$1,409
Fluocinonide27$1,375
Imiquimod56$1,269
Clobetasol Propionate28$1,245
Betamethasone Dipropionate25$1,157
Metronidazole23$1,150
Doxycycline Hyclate36$1,025
Fluticasone Propionate24$644
Spironolactone58$591
Hydroxychloroquine Sulfate23$543
ValacyclovirValacyclovir Hcl15$478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$51,459$131,07627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 44 dermatology providers in South Dakota.

Other dermatology in Aberdeen

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →